LANGUAGE:
LANGUAGE:
Our people are our pride, helping companies resonate with their customers for 20+ years.
We create, transform, test, and train more content than anyone in the world – from text, voice, audio, video, to structured & unstructured data.
Solutions
Our experts know the in-and-outs of your industry & its challenges.
Harness the Lionbridge Lainguage Cloud to support your end-to-end localization and content lifecycle
Our people are our pride, helping companies resonate with their customers for 20+ years.
About Us
Key Facts
Leadership
Insights
News
Trust Center
We create, transform, test, and train more content than anyone in the world – from text, voice, audio, video, to structured & unstructured data.
Content Services
Technical Writing
Training & eLearning
Financial Reports
Multicultural Marketing
Digital Experience Assessments
Translation Services
Translation
Video Localization
Software Localization
Website Localization
Translation for Regulated Companies
Interpretation
Multilingual SEO & Digital Marketing
Content Optimization
Testing Services
Functional QA & Testing
Compatibility Testing
Interoperability Testing
Performance Testing
Accessibility Testing
UX/CX Testing
Solutions
Digital Marketing
Live Events
Machine Translation
Our Knowledge Hubs
Positive Patient Outcomes
Future of Localization
Innovation to Immunity
COVID-19 Resource Center
Disruption Series
Patient Engagement
Lionbridge Insights
Our experts know the in-and-outs of your industry & its challenges.
Life Sciences
Banking & Finance
Retail
E-Commerce
Games
Automotive
Consumer Packaged Goods
Technology
Industrial Manufacturing
Legal Services
Travel & Hospitality
Harness the Lionbridge Lainguage Cloud to support your end-to-end localization and content lifecycle
Lainguage Cloud™ Platform
Connectivity
Translation Community
Workflow Technology
Smairt Content™
Smairt MT™
Smairt Data™
Language Quality
Analytics
SELECT LANGUAGE:
In our latest series on COVID-19, Lionbridge experts offer perspectives on the ecosystem of clinical development and regulatory approvals during the pandemic and in the future.
With our scale, service excellence and suite of language, communication and technology solutions, Lionbridge is well positioned to help you develop and deliver safe medicines and market them globally.
The COVID-19 crisis continues wreaking havoc with lives and livelihoods. The cost is often measured in lives lost, but in fact extends beyond those numbers. The associated public health measures put in place to manage the crisis, such as closing of public spaces and travel-related restrictions, have weighed on everyone. While aimed at curbing the spread of the virus, these measures can also have serious personal, social and economic consequences.
This stress has keenly affected patients across the spectrum of diseases. A PatientView survey of 1,720 patient organizations across 27 countries reveals that the prevailing mood among patients has been that of vulnerability and uncertainty. Patients feel they’ve been sidelined by their healthcare systems and have received diminished support from pharmaceutical companies due to pauses in patient-related activities during the pandemic.
Governments, scientific institutions and the life sciences sector have committed to bringing the crisis to an end by delivering vaccines and national immunization programs against COVID-19 at highly aggressive timelines. And yet, the emergence of first (albeit temporary) regulatory approvals for COVID-19 vaccines and the rollout of vaccination campaigns have been greeted by the public with mixed reactions and have sparked debates about vaccine acceptance.
The debates around the benefits and risks of vaccines are not a new or unusual phenomenon. While the scientific community is in agreement on the benefits of vaccines and herd immunity, the public at large is not as sure. The percentage of communities that trust vaccines varies depending on geography, culture, health literacy, personal beliefs, past experiences, expectations and trust in healthcare systems.
Effective community and patient engagement is critically important in the effort to maximize the acceptance of immunization programs.
The COVID-19 pandemic has brought into sharp focus the need for such engagement, especially because underserved population groups have been disproportionally affected by the pandemic. Being at high risk for socio-economic hardship and health literacy disparities makes these groups particularly prone to being left behind in the context of community engagement, health education and, ultimately, immunization uptake.
The goal of community engagement is to provide information and education addressed to specific target groups in order to enable action. There is no one-fits-all approach, but in all cases, transparency in communication is critical to support informed decision-making on vaccination.
In this respect, the overarching principles of informed consent in health care should guide the communication approach and preparation of information tools for diverse populations:
The COVID-19 pandemic has filled the information space with the language typically used by professionals. Words like “herd immunity,” “assessment of safety and efficacy” and “clinical trials” have become part of the daily news. In response, public interest in better understanding specific terminology (and the wider research setting behind them) has increased. This presents an opportunity for vaccine developers, public health authorities and other involved stakeholders to use situational momentum and expand community-focused engagement activities.
As the current pandemic has shown, volume of information, available through the Internet and other media sources, does not necessarily equate to its usefulness or acceptability.
Targeted and culturally tailored communication is essential throughout the entire lifecycle of a vaccine product and of a vaccine campaign in order to achieve immunization goals. Reaching out to communities, helping them improve their health literacy and encouraging their active participation in decisions about their health care are bound to build greater trust, leading to improved engagement among the public, industry and authorities and, most importantly, better health outcomes.